All posts by Kristin Schmotzer

Aptar and Adapt Pharma Donate 5,000 Doses of NARCAN® to Opioid C...

Over the past decade, opioid overdoses have killed nearly 11,000 people in Illinois, and the crisis continues to take a toll on the community. In 2016 alone, nearly 2,000 people died of opioid overdoses in Illinois, an 82 percent increase in just three years.

Community leaders are spearheading the charge to combat the epidemic by raising awareness of substance abuse and working to provide life-saving solutions to those who need it most.

To support the fight, Aptar and Adapt Pharma donated 5,000 doses of NARCAN® (naloxone) Nasal Spray, which can reverse the effects of an opioid overdose, to the State of Illinois and McHenry County. With headquarters in Crystal Lake, Illinois, Aptar recognized the need in its home state – and its home county of McHenry – for increased access to NARCAN®.

Of the donation, 4,000 doses went to Illinois Governor Bruce Rauner’s Opioid Overdose Prevention and Intervention Task Force and 1,000 doses went to the McHenry County Substance Abuse Coalition. The doses will largely benefit Illinois State Police in the line of action, and the Illinois criminal justice system, giving parole agents a tool to help save lives in the field. Additional doses will support Chicago Recovery Alliance’s mission of harm reduction, as well as education and distribution programs in McHenry County.

The donations were presented to Governor Rauner’s Task Force in a ceremony at the Chicago Recovery Alliance on February 8. Aptar CEO Stephan Tanda joined Governor Rauner and Lieutenant Governor Evelyn Sanguinetti, along with other key experts and leaders, to discuss the impact of the crisis, the mission of the Governor’s Task Force, and how donations like the one made by Aptar and Adapt provide a critical treatment option to those on the front lines.

A second ceremony was held on February 9 at the McHenry County Sheriff’s Office. Tanda was joined by State’s Attorney Patrick Kenneally and McHenry County Substance Abuse Coalition Chairman, Jason Sterwerf, along with other community leaders.

Aptar and Adapt’s industry-first, FDA-approved, needle-free nasal spray device does not require assembly or specialized training, which means a dose of NARCAN® can be easily and quickly administered by anyone, anywhere. First responders can instantaneously deliver naloxone, instead of spending precious time fiddling with a syringe and needle. Time is critical when someone’s life is on the line, and Aptar and Adapt’s faster drug delivery innovation increases the chance of reversing the effects of an opioid overdose and saving a life.

NARCAN® Nasal Spray is not a substitute for emergency medical care, and repeat applications may be necessary. Seek emergency medical assistance immediately after initial use, keeping the patient under continued surveillance.

Click here to download the full press release. For more information, please email newsroom@aptar.com.

(Photo L-R: Patrick Finlon, Cary Grove Chief of Police; Matt DellaMaria, SVP, Investor Relations & Communications, Aptar; Jason Sterwerf, Chairman, McHenry County Substance Abuse Coalition; Stephan Tanda, President and CEO, Aptar; Laura Crain, Director, McHenry County Substance Abuse Coalition; Laura Fry, Director, Live4Lali; Leslie Schermerhorn, Superintendent, McHenry County Regional Office of Education; Patrick Kenneally, McHenry County State’s Attorney; Bill Prim, McHenry County Sheriff)

February 13, 2018

Aptar Reports Fourth Quarter and Annual Results

Crystal Lake, Illinois, February 12, 2018 — AptarGroup, Inc. (NYSE:ATR) today reported fourth quarter and annual results for 2017. The Company also announced details of its business transformation plan and affirmed its long-term financial targets.

Fourth Quarter Summary

  • Reported sales increased 16% driven by robust core sales growth in each business segment (+ 10%) and the positive effect of currency rates (+ 6%)
  • Core sales increased in each end market and in each region
  • Reported net income (8% of net sales) was $50 million (equal to the prior year)
  • Adjusted EBITDA (19% of net sales) increased to $118 million (+ 9%)
  • Reported earnings per share of $0.77 (equal to the prior year) included negative impacts of recently enacted tax reform legislation
  • Comparable adjusted earnings per share of $0.81 vs. $0.77 in the prior year (+ 5%)
  • Business transformation plan to drive growth and yield annual recurring incremental EBITDA of approximately $80 million by the end of 2020 with implementation costs expected to be approximately $90 million

Annual Summary

  • Reported sales increased 6% to $2.5 billion primarily from core sales growth in each business segment (+ 4%), positive effect of currency rates (+ 1%) and the effects of an acquisition completed in early 2016 (+ 1%)
  • Reported annual net income (9% of net sales) increased to $220 million (+ 7%)
  • Adjusted annual EBITDA (19% of net sales) of $475 million (slight decrease)
  • Reported annual earnings per share of $3.41 vs. $3.17 in the prior year (+ 8%)
  • Comparable adjusted annual earnings per share of $3.44 vs. $3.26 in the prior year (+ 6%)
  • Paid increased annual dividend for the 24th consecutive year

Download the full press release.

February 13, 2018

Aptar Welcomes Two New Members to its Board of Directors

Aptar elected Craig Owens and Jesse Wu to its Board of Directors, effective February 1, 2018. Both Mr. Owens and Mr. Wu are standout appointments with specialized experiences and insights that align with Aptar’s ongoing business strategy and objectives.

Mr. Owens, for example, is no stranger to the food and beverage industries, having served as Chief Financial Officer and Administrative Officer of Campbell Soup Company. He was also the Chairman of the company’s Operating Committee. During his tenure in those roles, the company completed a number of high value transactions, including the $1.6 billion acquisition of Bolthouse Farms, one of Campbell’s largest acquisitions to-date.

Earlier in his career, he worked for Cocoa-Cola as Region Director of Italy, Austria and Switzerland. Mr. Owens also currently serves on the Boards of Dean Foods, United States Cold Storage and J.C. Penny.

Food and beverage are high priority markets for Aptar, and Mr. Owen’s deep expertise will be invaluable as the Company continues to forge growth in those spaces.

Mr. Wu advises private equity firms and previously held senior leadership roles at Johnson & Johnson, including Chairman of Johnson & Johnson China and Worldwide Chairman of the company’s Consumer Healthcare Division. He oversaw the $15 billion Consumer and OTC business, and led the $300 million integration of Beijing Dabao Cosmetics Co., Ltd. to further expand the company’s presence in the Chinese market.

He currently serves on the Board of the A2 Milk Company, which is dual listed on the Australia and New Zealand Stock Exchanges. He also serves on the Board of Shanghai Kehua Bio-Engineering, which is listed on the Shenzhen Stock Exchange, and on the Board of Li Ning Company Limited, which is listed on the Hong Kong Stock Exchange.

His knowledge of Asian markets and high growth economies worldwide will prove critical as Aptar continues to prioritize penetrating and deepening its footprint in these regions.

The Board is pleased to welcome Mr. Owens and Mr. Wu, and looks forward to the contributions they will make as Aptar continues to deliver value to its customers and shareholders.

Click here to download the full press release, or contact newsroom@aptar.com for more information.

(Photo: L – Mr. Craig Owens; R – Mr. Jesse Wu)

January 24, 2018

Aptar Chairman King Harris to Retire, George Fotiades Appointed S...

After 40 years of insightful guidance and dedicated oversight, Aptar Chairman of the Board King Harris will retire, effective May 2, 2018. Mr. Harris oversaw Aptar’s predecessor businesses when they were part of Pittway Corporation where he played a critical role in fostering the original vision for Aptar. He has served on Aptar’s Board since it became a stand-alone public company in 1993 and was appointed Chairman of the Board in 1995.

His tireless leadership nurtured new thinking and shaped Aptar into a leading provider of dispensing and drug delivery solutions. He leaves an important legacy at Aptar that will continue to play a role in cultivating a company culture of success and innovation.

Aptar’s Board of Directors has elected current director, George Fotiades, to replace Mr. Harris upon his retirement. A member of the company’s Board since 2011, Mr. Fotiades is an accomplished leader, having previously served as president and chief operating officer of Cardinal Health, Inc., and in various leadership positions at Fortune 500 companies, including Bristol-Myers Squibb and Procter & Gamble.

With a deep understanding of Aptar’s strategy, markets and competitive advantages, Mr. Fotiades has been a valued member of the Board and is well-positioned for the role of Chairman.

In the coming months, Mr. Harris and Mr. Fotiades, along with the rest of the Board, will work together to ensure a seamless transition. The Board is grateful for Mr. Hariss’ valued leadership and looks forward to continued success under Mr. Fotiades’ direction.

Click here to download the full press release, or email newsroom@aptar.com for more information.

(Photo: L – Mr. King Harris; R – Mr. George Fotiades)

January 22, 2018

AptarGroup Announces Quarterly Conference Call and Annual Meeting...

Crystal Lake, Illinois, January 3, 2018 – AptarGroup, Inc. (NYSE: ATR) announced the dates and times of quarterly conference calls for the year. Any updates to these dates or times will be communicated in subsequent press releases.

 

Quarterly Conference Calls

Press Release (1) Conference Call (2)
4th Quarter and Annual 2017 Results February 12, 2018 February 13, 2018, at 8:00 a.m. CT
1st Quarter 2018 Results April 26, 2018 April 27, 2018, at
8:00 a.m. CT
2nd Quarter 2018 Results July 26, 2018 July 27, 2018, at
8:00 a.m. CT
3rd Quarter 2018 Results October 25, 2018 October 26, 2018, at  8:00 a.m. CT

 

(1) Press releases will be issued on the dates noted after the close of trading on the New York Stock Exchange.

(2) Times shown are in the Central U.S. time zone. Conference calls will last approximately one hour and interested parties are invited to listen to a live webcast by visiting the Investor Relations page of the Aptar website at www.aptar.com. Replay of the conference calls can also be accessed on the Investor Relations page of the website.

Annual Meeting

The Board also announced that the 2018 Annual Meeting of Stockholders will be held at the offices of Sidley Austin LLP, One South Dearborn Street, Chicago, Illinois, on May 2, 2018, at 9:00 a.m. CT. The record date for stockholders entitled to vote at the meeting is March 9, 2018.

Click here to download the full press release.

January 3, 2018